{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_names_name in Any Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT03538327: Phase 4 Interventional Completed Hypertension
(2013)
Source URL:
First approved in 2016
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/ucm071835.htm laxative:stimulant laxative sennosides a and b
Source URL:
First approved in 1998
Source:
21 CFR 334
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
Maltos-10 by Otsuka [Japan]
Source URL:
First approved in 1995
Source:
BLA103649
Source URL:
Class:
MIXTURE
Maltose, a disaccharide, is found mainly in grains and cereals. Nutritionally, maltose provides the same number of calories as starches and other sugars. Maltose can be the agent responsible for the primary signals to induce the sensations of hunger and satiation in human beings. It was shown, that parenterally administered maltose could be of clinical value.
Status:
Possibly Marketed Outside US
Source:
Butirosin by SigmaAldrich
Source URL:
Class:
MIXTURE
Butirosin is water-soluble aminoglycosidic antibiotic complex which is active against both Gram-positive and Gram-negative bacteria. Butirosin is less toxic than neomycin and shows a good antibacterial activity, including Pseudomonas aeruginosa, which is resistant to neomycin, ribostamycin and kanamycin.
Status:
US Approved Rx
(2013)
First approved in 2007
Class:
PROTEIN
Status:
US Approved Rx
(2003)
Source:
BLA103979
(2003)
Source URL:
First approved in 2003
Source:
BLA103979
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1986)
Source:
BLA103132
(1986)
Source URL:
First approved in 1986
Source:
BLA103132
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03457948: Phase 2 Interventional Active, not recruiting Metastatic Malignant Neoplasm in the Liver
(2018)
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2024)
Source:
NDA218614
(2024)
Source URL:
First approved in 2024
Source:
NDA218614
Source URL:
Class:
NUCLEIC ACID
Status:
US Approved Rx
(2023)
Source:
NDA215842
(2023)
Source URL:
First approved in 2023
Source:
NDA215842
Source URL:
Class:
NUCLEIC ACID
